MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 571138 | Name: Cefmenoxime free base

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cefmenoxime (free base) is a cephalosporin antibiotic administered intravenously or intramuscularly. It is active against most common gram-positive and gram-negative microorganisms. It is a potent inhibitor of Enterobacteriaceae, and is resistant to beta-lactamase-initiated hydrolysis. The drug has a high success rate against many types of infection.

Chemical Structure

Cefmenoxime free base
CAS#65085-01-0 (free base)

Theoretical Analysis

MedKoo Cat#: 571138

Name: Cefmenoxime free base

CAS#: 65085-01-0 (free base)

Chemical Formula: C16H17N9O5S3

Exact Mass: 511.0515

Molecular Weight: 511.55

Elemental Analysis: C, 37.57; H, 3.35; N, 24.64; O, 15.64; S, 18.80

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
75738-58-8 (HCl) 65085-01-0 (free base) 65085-02-1 (sodium)
Synonym
Cefmenoxime; A50912; A 50912; A-50912; AB 50912
IUPAC/Chemical Name
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-, (6R-(6alpha,7beta(Z)))-
InChi Key
HJJDBAOLQAWBMH-YCRCPZNHSA-N
InChi Code
InChI=1S/C16H17N9O5S3/c1-24-16(20-22-23-24)33-4-6-3-31-13-9(12(27)25(13)10(6)14(28)29)19-11(26)8(21-30-2)7-5-32-15(17)18-7/h5,9,13H,3-4H2,1-2H3,(H2,17,18)(H,19,26)(H,28,29)/b21-8-/t9-,13-/m1/s1
SMILES Code
O=C(C(N12)=C(CSC3=NN=NN3C)CS[C@]2([H])[C@H](NC(/C(C4=CSC(N)=N4)=N\OC)=O)C1=O)O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 511.55 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Eicken A, Schöber JG, Roos R, Machka K. Cerebrospinal fluid penetration of cefmenoxime in children with bacterial meningitis. Infection. 1991 Nov-Dec;19(6):406-8. PubMed PMID: 1816111. 2: Washida H, Tsugaya M, Hirao N, Sakagami H, Iwase Y. [Pharmacokinetic study of cefmenoxime concerning its transfer into tissues]. Jpn J Antibiot. 1985 Jun;38(6):1648-53. Japanese. PubMed PMID: 3862883. 3: Stamm JM, Girolami RL, Shipkowitz NL, Bower RR. Antimicrobial activity of cefmenoxime (SCE-1365). Antimicrob Agents Chemother. 1981 Mar;19(3):454-60. PubMed PMID: 6264846; PubMed Central PMCID: PMC181453. 4: Kita Y, Itakura K, Tsuchiya K, Imada A. Pharmacokinetics of SCE-1141, a stereoisomer of cefmenoxime, in rats. J Antimicrob Chemother. 1986 Feb;17(2):205-13. PubMed PMID: 3457784. 5: Tsuchiya K, Kondo M, Kida M, Nakao M, Iwahi T, Nishi T, Noji Y, Takeuchi M, Nozaki Y. Cefmenoxime (SCE-1365), a novel broad-spectrum cephalosporin: in vitro and in vivo antibacterial activities. Antimicrob Agents Chemother. 1981 Jan;19(1):56-65. PubMed PMID: 6941742; PubMed Central PMCID: PMC181357. 6: Sennello LT, Quinn D, Rollins DE, Tolman KG, Sonders RC. Effect of probenecid on the pharmacokinetics of cefmenoxime. Antimicrob Agents Chemother. 1983 Jun;23(6):803-7. PubMed PMID: 6311084; PubMed Central PMCID: PMC184968. 7: Machinist JM, Bopp BA, Quinn D. Metabolism of [14C]Cefmenoxime in normal subjects after intramuscular administration. Antimicrob Agents Chemother. 1984 Oct;26(4):431-5. PubMed PMID: 6097162; PubMed Central PMCID: PMC179939. 8: Campoli-Richards DM, Todd PA. Cefmenoxime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1987 Aug;34(2):188-221. Review. PubMed PMID: 3304966. 9: Matsumoto K, Nagatake T, Uzuka Y, Harada T, Rikitomi N. Laboratory evaluation of cefmenoxime: a new cephalosporin. In vitro and in vivo antibacterial activities and pharmacokinetic properties. Chemotherapy. 1983;29(2):80-8. PubMed PMID: 6301776. 10: Robens W. Concentrations of cefmenoxime in human tissues. Am J Med. 1984 Dec 21;77(6A):32-3. PubMed PMID: 6097121. 11: Tsuchiya K, Kita Y, Yamazaki I, Kondo M, Noji Y, Fugono T. Absorption, distribution and excretion of cefmenoxime (SCE-1365), a novel broad-spectrum cephalosporin, in mice, rats, rabbits and dogs. J Antibiot (Tokyo). 1980 Dec;33(12):1532-44. PubMed PMID: 6941956. 12: Husson MO, Izard D, Bryskier A, Vincent P, Leclerc H. Combination effect of cefmenoxime with four aminoglycosides on Enterobacteriaceae susceptible and moderately susceptible to this new cephalosporin. Zentralbl Bakteriol Mikrobiol Hyg A. 1984 Aug;257(3):383-7. PubMed PMID: 6091368. 13: Fuchs PC, Jones RN, Thornsberry C, Barry AL, Gerlach EH, Sommers HM. Cefmenoxime (SCE-1365), a new cephalosporin: in vitro activity, comparison with other antimicrobial agents, beta-lactamase stability, and disk diffusion testing with tentative interpretive criteria. Antimicrob Agents Chemother. 1981 Dec;20(6):747-59. PubMed PMID: 6275784; PubMed Central PMCID: PMC181794. 14: Nakao M, Yukishige K, Kondo M, Imada A. Novel morphological changes in gram-negative bacteria caused by combination of bulgecin and cefmenoxime. Antimicrob Agents Chemother. 1986 Sep;30(3):414-7. PubMed PMID: 3535665; PubMed Central PMCID: PMC180571. 15: Schentag JJ, Smith IL, Swanson DJ, DeAngelis C, Fracasso JE, Vari A, Vance JW. Role for dual individualization with cefmenoxime. Am J Med. 1984 Dec 21;77(6A):43-50. PubMed PMID: 6097124. 16: Serieys C, Bergogne-Berezin E, Kafe H, Bryskier A. Study of the diffusion of cefmenoxime into the bronchial secretions. Chemotherapy. 1986;32(1):1-6. PubMed PMID: 3456295. 17: Yamazaki I, Shirakawa Y, Fugono T. Comparison of the renal excretory mechanisms of cefmenoxime and other cephalosporins: effect of para-aminohippurate on renal clearance and intrarenal distribution of cephalosporins in rabbits. J Antibiot (Tokyo). 1981 Nov;34(11):1476-85. PubMed PMID: 6274834. 18: Pangon B, Joly V, Vallois JM, Abel L, Buré A, Brion N, Contrepois A, Carbon C. Comparative efficacy of cefotiam, cefmenoxime, and ceftriaxone in experimental endocarditis and correlation with pharmacokinetics and in vitro efficacy. Antimicrob Agents Chemother. 1987 Apr;31(4):518-22. PubMed PMID: 3300530; PubMed Central PMCID: PMC174769. 19: Schentag JJ, Reitberg DP, Cumbo TJ. Cefmenoxime efficacy, safety, and pharmacokinetics in critical care patients with nosocomial pneumonia. Am J Med. 1984 Dec 21;77(6A):34-42. PubMed PMID: 6097122. 20: Weissenbacher ER, Adams D, Gutschow K, Peters-Welte C, Luehr HG. Clinical results and concentrations of cefmenoxime in serum, amniotic fluid, mother's milk, and umbilical cord. Am J Med. 1984 Dec 21;77(6A):11-2. PubMed PMID: 6097116.

View History

Cefoxazole

Cefoxazole